Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Edwin DeJesus(Orlando Immunology Center), Jürgen K. Rockstroh(University of Bonn), Keith Henry(Hennepin County Medical Center), Jean‐Michel Molina(Assistance Publique – Hôpitaux de Paris), Joseph Gathe, S. Ramanathan(Gilead Sciences (United States)), Xuelian Wei(Gilead Sciences (United States)), Kitty Yale(Gilead Sciences (United States)), Javier Szwarcberg(Gilead Sciences (United States)), Kirsten White(Gilead Sciences (United States)), Andrew Cheng(Gilead Sciences (United States)), Brian P. Kearney(Gilead Sciences (United States))
The Lancet
June 1, 2012
10.1016/s0140-6736(12)60918-0
Cited by 346Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis